The level of investment in medical technology has been erratic of late, with July and August financings each totaling in excess of $400 million, while October financings barely crossed $200 million (and would have been much less if not for a $40 million by Direct Flow Medical and $55 million by TransEnterix). See the trend.
November medtech financings have gotten off to a good start (at almost $200 million by mid-month), but short of a pre-Thanksgiving holiday venture capital investment surge (would that there was such a thing), total venture capital funding to medtech will likely hit the flat trend of around $300 million. The biggest fundings include the following:
- $30M, Fate Therapeutics, Inc., has raised $30 million in a Series B financing (induced pluripotent stem cell technology platform)
- $30M, Entellus Medical, Inc., has raised $30 million in a series D funding (less invasive treatment of sinusits)
- $27M, Spinal Modulation, Inc., has raised $27.4 million in a Series C financing (therapeutic devices for treatment of chronic pain)
- $21M, On-Q-ity has raised $21 million in a Series A round (cancer cell detection and testing platform)
- $16M, Activaero GmbH has raised $16 million in a Series A financing (pulmonary drug delivery device)
bookmark to
Pace of investment in medical technology: up, down, static
Post a Comment